OBJECTIVE: Highly active antiretroviral therapy (HAART) can produce marked increases in peripheral blood CD4+ T cells and decreases in HIV plasma RNA copy numbers. However, it is not clear whether these absolute changes will be accompanied by a recovery in the known naive CD4+ T cell depletion or a decrease in the marked CD8+ T cell activation. DESIGN: Twenty-nine patients were enrolled in studies of either nucleoside therapy alone or nucleoside therapy combined with a protease inhibitor (zidovudine + lamivudine + indinavir). One hundred and ninety-one examinations were carried out at three baseline time points and during 40 weeks of follow-up to evaluate the effect of HAART on CD4+ memory/naive phenotype and CD8+ T cell activation. METHODS: CD4+ and CD8+ T cell number, CD62L/CD45RA expression on CD4+ T cells and CD38 expression on CD8+ T cells were measured by three-color flow cytometry. RESULTS: Most protease inhibitor treated patients had a significant rise in CD4+ numbers. The marked rise in the CD4+ T cells seen in individuals in this study was not accompanied over a 40-week period by a change in the abnormally low CD4+ naive compartment, and thus was almost completely of memory phenotype. The CD38 expression on CD8+ cells fell during treatment, and decreased to a greater degree than the comparable rise in CD4+ T cell counts. This decrease continued in many patients after the CD4+ T cell rise or viral load decline had plateaued. CONCLUSION: HAART results in changes in activation to a greater extent than absolute changes in CD4+ T cell numbers, but is not accompanied by an increase in naive CD4+ T cells. Measurements of CD4+ T cell numbers alone may not allow appropriate interpretation of immune activation or immune competence in patients receiving those drugs.
OBJECTIVE: Highly active antiretroviral therapy (HAART) can produce marked increases in peripheral blood CD4+ T cells and decreases in HIV plasma RNA copy numbers. However, it is not clear whether these absolute changes will be accompanied by a recovery in the known naive CD4+ T cell depletion or a decrease in the marked CD8+ T cell activation. DESIGN: Twenty-nine patients were enrolled in studies of either nucleoside therapy alone or nucleoside therapy combined with a protease inhibitor (zidovudine + lamivudine + indinavir). One hundred and ninety-one examinations were carried out at three baseline time points and during 40 weeks of follow-up to evaluate the effect of HAART on CD4+ memory/naive phenotype and CD8+ T cell activation. METHODS:CD4+ and CD8+ T cell number, CD62L/CD45RA expression on CD4+ T cells and CD38 expression on CD8+ T cells were measured by three-color flow cytometry. RESULTS: Most protease inhibitor treated patients had a significant rise in CD4+ numbers. The marked rise in the CD4+ T cells seen in individuals in this study was not accompanied over a 40-week period by a change in the abnormally low CD4+ naive compartment, and thus was almost completely of memory phenotype. The CD38 expression on CD8+ cells fell during treatment, and decreased to a greater degree than the comparable rise in CD4+ T cell counts. This decrease continued in many patients after the CD4+ T cell rise or viral load decline had plateaued. CONCLUSION: HAART results in changes in activation to a greater extent than absolute changes in CD4+ T cell numbers, but is not accompanied by an increase in naive CD4+ T cells. Measurements of CD4+ T cell numbers alone may not allow appropriate interpretation of immune activation or immune competence in patients receiving those drugs.
Authors: K S Froebel; G M Raab; C D'Alessandro; M P Armitage; K M MacKenzie; M Struthers; J M Whitelaw; S Yang Journal: Clin Exp Immunol Date: 2000-10 Impact factor: 4.330
Authors: Martin Montes; Cesar Sanchez; Dorothy E Lewis; Edward A Graviss; Carlos Seas; Eduardo Gotuzzo; A Clinton White Journal: J Infect Dis Date: 2010-12-21 Impact factor: 5.226
Authors: Samir P Bhagwat; Francis Gigliotti; Haodong Xu; Terry W Wright Journal: Am J Physiol Lung Cell Mol Physiol Date: 2006-08-04 Impact factor: 5.464
Authors: Marcus Buggert; Son Nguyen; Gonzalo Salgado-Montes de Oca; Bertram Bengsch; Samuel Darko; Amy Ransier; Emily R Roberts; Daniel Del Alcazar; Irene Bukh Brody; Laura A Vella; Lalit Beura; Sathi Wijeyesinghe; Ramin S Herati; Perla M Del Rio Estrada; Yuria Ablanedo-Terrazas; Leticia Kuri-Cervantes; Alberto Sada Japp; Sasikanth Manne; Shant Vartanian; Austin Huffman; Johan K Sandberg; Emma Gostick; Gregory Nadolski; Guido Silvestri; David H Canaday; David A Price; Constantinos Petrovas; Laura F Su; Golnaz Vahedi; Yoav Dori; Ian Frank; Maxim G Itkin; E John Wherry; Steven G Deeks; Ali Naji; Gustavo Reyes-Terán; David Masopust; Daniel C Douek; Michael R Betts Journal: Sci Immunol Date: 2018-06-01